George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Glad to have subscribed under the offer. This will be back up to £1 in no time I believe.
GLA
Rorydinho
You have mentioned:
"I’m invested in late clinical stage biotechs which are valued similarly but have much more data, efficacy data, fast-track, ODD, everything that Avacta doesn’t have".
I say:- Good luck to you. HOWEVER, WHAT AVACTA HAS IN TERMS OF ITS CHEMICAL PLATFORM, pre/CISION WHICH, USING EXISTING CHEMOTHERAPY DRUG, SAVE HEALTHY CELLS. NO OTHER BIO COMPANY HAS SUCH PLATFORM, AND, THAT IS THE BIGGEST DIFFERENCE.
UNLIKE AVACTA, MOST BIO COMPANIES, IN SEARCH OF A NEW DRUG, ARE BINARY AND WILL FAIL .
If anyone, I suspect its Gervaise Heddle
Nearvana
Please can you inform where to find this info regarding private investor. Thanks
Great posts Shearclass and Gallmat
That's great. Thanks
I believe they cannot sit for 5 years before paying us. The International court will give a timeframe within which they have to settle - OTHERWISE I understand we can go after the state owned assets held abroad
Indeed Mickey.
The management have likely become aware of some development.
Is it:
A) Amazing news from west Africa or
B) some sort of hint on the Bhukia
We will soon find out
GLA
Excellent news.
They know their share are gonna worth a fortune in time to come.
GLA
Indeed Adhellas - PAT is under India - Australia bilateral treaty.
As regards UK - India treaty, I only mentioned this since I came across this recently and was simply trying to draw attention on this BB that India is also trying recently with other countries to have the cases heard according to local laws be actually part of the trade treaties which UK was not accepting.
I am increasingly coming of the view that, the government of India, with their new policy of shutting outside ownership and the rudness in their tone, will not budge and likely not respond to the initial notice sent by PAT.
This leaves PAT to send the arbitration letter to the GOI which I think will coincide the start of the auction. So we should know what the claim amount is going to be pretty soon. I think the low ball to be $1.2 billion - any lower will be disappointing.
I was reading an article covering UK and India bilateral trade treaty negotiations and it had come to a sticking point because UK were saying no to India's insistence that any investment dispute be conducted according the local laws being exhausted first. UK is arguing that the dispute resolution has to be conducted through international courts. I HOPE, IN ORDER TO WIN BUSINESS, THE UK DON'T GIVE UP ON THIS VERY IMPORTANT POINT OTHERWISE WE ARE SCREWED.
"Don’t you think that if the C7 data is so good that Al would have published it before the cash raise in order to push the SP up and get a decent offer price?"
I believe the company has to be very careful in releasing data PREMATURELY just for the sake of raising funds at a higher share price and in the process jeopardise the very existence of the company.
I am truly staggered.
I say to myself, try finding another bio company that has the immense potential as good as Avacta. What I think will happen is that those in angry mode will gradually come back buying simply because of the potential AVACTA has to offer.
I agree this fund raise should have been done when the share price was much higher. But, we are where we are and the company is now in a strong state
GLA
Indeed Hopeful
I had accumulated 2.5 million of those and panic sold as had developed distrust for the CEO, but you learn by mistake.
Thanks Shearclass for the posts, I feel very confident about this one.
GLA
Has clearly shifted in Avacta's favour, with this fundraise, in any deal/ negotiations with big pharma companies that it might enter into - hopeful for news on this front in the near future
From 15:17
"WHAT WE ARE FINDING OUT NOW FROM PHARMA PARTNERS THAT WE ARE TALKING TO IS THAT THEY ARE QUITE PREPARED TO CONSIDER LICENCING AND PARTNERING ASSETS INTO THIS PIPELINE BEFORE WE GET INTO THE CLINIC SO THAT'S A VERY INTERESTING ANGLE THAT WE HAD NIT ANTICIPATED AND SO WHAT WE ARE DOING IN THE NEXT 12 NONTHS IS PUTTING MORE RESOURCE INTO BUILDING OUT THIS PIPELINE TO MAKE ASSETS THAT WE BELIEVE ARE GOING TO BE LICENSABLE".
https://www.sharesmagazine.co.uk/video/alastair-smith-ceo-of-avacta-avct
Wow, I had piled mine in the bottom drawer. At last, some movement here.
Always had belief in Haneti. Let's see some funding going into drilling the vast sites
By the way, over at Katoro Gold, RNS states Gervaise Heddle has purchased 57,000,000 shares, I.e. 3.8 per cent in the company. My shares now out of the bottom drawer
I wrote to MB asking if there was a Director dealing . Complete silence
"Simon has over 26 years' commercial experience in the biopharma industry. He has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development. Simon has been involved in over 80 commercial deals across Europe, North America, Australasia, Japan, Russia/CIS and South America".
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"As Chief Business Officer, Simon will work closely with the senior management team and lead commercial strategy and business development activities at this exciting period in the Company's development as compelling clinical data emerges from the AVA6000 phase 1 trial".
"These emerging data give us, for the first time, the opportunity to accelerate ongoing discussions as well as to generate new opportunities through our business development activities aimed at delivering licensing opportunities for the pre|CISIONTM and Affimer® platforms."